Chronic kidney disease in type 2 diabetes (NICE TA877)
1.1 Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if:
• it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
－ angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
－ sodium–glucose cotransporter-2 (SGLT2) inhibitors and
• the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/ 1.73 m 2 or more.
Reason for decision:
Suitable for initiation in primary care